BioAffinity Technologies Inc. (BIAFW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
BioAffinity Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 55,041 | $18,163.93 | $9,356.97 | -$8,806.96 | -48.49% |
BioAffinity Technologies Inc. (BIAFW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioAffinity Technologies Inc. ever had a stock split?
BioAffinity Technologies Inc. Profile
| Professional Services Industry | Industrials Sector | Maria Zannes CEO | NASDAQ (CM) Exchange | 09076W117 CUSIP |
| US Country | 57 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
bioAffinity Technologies, Inc. is a biotechnology company focusing on the health sector, specifically in the early detection of lung cancer and related pulmonary diseases. Established in 2014, the company operates with the vision of transforming cancer diagnostics through non-invasive techniques that enhance early detection and subsequent treatment outcomes. Based in San Antonio, Texas, bioAffinity Technologies strives to address the critical need for early lung cancer screening tools that can significantly reduce mortality rates through early intervention.
Products and Services
- CyPath Lung
bioAffinity Technologies' flagship product, CyPath Lung, is a pioneering diagnostic test designed for the early detection of lung cancer. Utilizing a non-invasive approach, this diagnostic tool aims to identify lung cancer at an early stage when treatment can be most effective. By catering to the need for less invasive, more patient-friendly screening options, CyPath Lung represents a significant advancement in the fight against lung cancer, potentially increasing survival rates through earlier diagnosis and treatment.
